Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$23.09 USD
+0.47 (2.08%)
Updated Feb 4, 2025 04:00 PM ET
After-Market: $23.08 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.09 USD
+0.47 (2.08%)
Updated Feb 4, 2025 04:00 PM ET
After-Market: $23.08 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
Zacks News
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
by Zacks Equity Research
We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.